Apotex Expands Metformin Hydrochloride Recall Due to Carcinogen

Written By Peter Jensen

Apotex has expanded a recall of Metformin Hydrochloride Extended-Release Tablets, USP 500mg due to the presence of N-nitrosodimethylamine (NDMA). The previously announced recall to the Retail Level has been expanded to the Consumer Level. The original recall was initiated on May 29, 2020, after testing revealed the NDMA, which is classified as a probable human carcinogen.
Staff Report, PR Newswire 06/05/2020   

Read Article: PR Newswire        

Peter Jensen
Previous

Injured Louisiana Woman's Lawsuit Alleges Nutri-Pot Pressure Cookers Are Defective
Next

Estate Sues After Man in Motorized Wheelchair Fatally Hit by Car